Source-grounded facts extracted from Elevance Health, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Elevance Health, Inc. reported FY 2026 results: EPS at least $26.75. Guidance raised.
“FY 2026 adjusted diluted EPS 2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility”
Elevance Health, Inc. reported first quarter 2026 results: revenue $49.5 billion, EPS $8.00. Guidance raised.
“ELEVANCE HEALTH REPORTS FIRST QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCE • 1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 • 1Q 2026 diluted EPS 1 of $8.00; adjusted diluted EPS 2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income”
Elevance Health, Inc. shareholders rejected Shareholder proposal requesting annual political activity reporting from certain third parties prior to the Company donating to the organizations at the 2024-05-15 meeting.
“Shareholder proposal requesting annual political activity reporting from certain third parties prior to the Company donating to the organizations. The shareholder proposal requesting annual political activity reporting from third parties prior to the Company donating to the organization was not approved based upon the following votes:”
Elevance Health, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP at the 2024-05-15 meeting.
“Ratification of the appointment of Ernst & Young LLP. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2024 was ratified based upon the following votes:”
Elevance Health, Inc. shareholders approved Advisory vote on the Company’s executive compensation at the 2024-05-15 meeting.
“Advisory vote on the Company’s executive compensation. The advisory vote on the compensation of the Company’s named executive officers was approved based upon the following votes:”
Elevance Health, Inc. shareholders approved Election of Directors at the 2024-05-15 meeting.
“Election of Directors. The following nominees for director were elected to serve three-year terms to expire at the Company’s annual meeting of shareholders in 2027 based on the following votes:”
Elevance Health, Inc. reported the quarter ended March 31, 2024 results: revenue $42.3 billion, EPS $9.59. Guidance raised.
“language in such filings. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 EARNINGS RELEASE ELEVANCE HEALTH REPORTS FIRST QUARTER 2024 RESULTS • 1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 • 1Q 2024 diluted EPS 1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS 2 of $10.64, up 12.5% • FY 2024 diluted EPS and adjusted diluted EPS”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.